Biotech Acquisition Company Unit
BIOTU
BIOTU was delisted on the 2nd of February, 2023.
41 hedge funds and large institutions have $65.8M invested in Biotech Acquisition Company Unit in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 22 closing their positions.
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
31% less funds holding
Funds holding: 59 → 41 (-18)
45% less capital invested
Capital invested by funds: $119M → $65.8M (-$53.7M)
82% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$1.93M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1.5M |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$538K |
| 4 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
+$230K |
| 5 |
Janus Henderson Group
London,
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$9.89M |
| 2 |
LA
Linden Advisors
New York
|
-$6.71M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$4.91M |
| 4 |
DCM
DG Capital Management
New York
|
-$4.45M |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$4.01M |
BIOTU Hedge Fund Activity: Q2 2021 in Review
41 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2021, worth a combined $65.8M — down 45% from $119M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BIOTU and 4 opened new positions — a net loss of 18 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Rivernorth Capital Management, adding an estimated $1.93M. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $9.89M sold.
- 41 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2021, down from 59 in Q1 2021.
- Funds reported $65.8M of Biotech Acquisition Company Unit stock for Q2 2021, down 45% quarter-over-quarter.
- 4 funds opened new Biotech Acquisition Company Unit positions in Q2 2021 and 22 closed out, a net change of -18 holders.
- The largest Biotech Acquisition Company Unit buyer in Q2 2021 was Rivernorth Capital Management, an estimated $1.93M added.
- The largest Biotech Acquisition Company Unit seller in Q2 2021 was BlueCrest Capital Management, an estimated $9.89M sold.
Based on aggregated 13F filings for Q2 2021.